Case report: Precision guided reactive cancer management: molecular complete response in heavily pretreated metastatic CRC by dual immunotherapy and sorafenib. (2024)

Peer-Reviewed Study · Esranur Aydın; Ünal Metin Tokat; Ashkan Adibi et al. · 2024

Esranur Aydın et al., 2024: Single-patient case report of metastatic colon cancer treated with dual checkpoint inhibitors plus mebendazole and lenvatinib under genomic and MRD guidance, reporting a molecular complete response.

immunotherapy was considered, employing dual immune checkpoint inhibitors alongside mebendazole and Lenvatinib targeting the WNT and VEGF/angiogenesis pathways.

Esranur Aydın et al., 2024: Single-patient case report of metastatic colon cancer treated with dual checkpoint inhibitors plus mebendazole and lenvatinib under genomic and MRD guidance, reporting a molecular complete response. Study type: case report (N=1). Country: Turkey (Medicana Health Group, Istanbul). Patient: 58-year-old male, metastatic colon adenocarcinoma with liver metastasis, heavily pretreated. Dose/route/schedule of mebendazole: not stated in the abstract text captured. Funder: not stated in the record. Declared conflicts: 'The authors declare that the research was conducted in the absence of any commercial or financial relationships…'. Comparator: none. PARTLY because the regimen contained four agents and response cannot be attributed to mebendazole; the case is also recorded here as patient-reported, not independently verified. Study type: case report.